-
Recordati: A Somehow Boring But Interesting Pharmaceutical Company
25 May 2018 00:24 GMT
… has shifted its traditional pharmaceutical business towards a more … a 15% CAGR decline.
Seloken/logimax: The franchise … is a latest generation statin indicated in the reduction … not tolerate the existing treatment. The drug is well tolerated per …
-
Cardiovascular Drugs Market to Reach a Valuation of US$162.96 Billion by 2025 Globally: Transparency Market Research
30 Oct 2017 13:45 GMT
… ;www.transparencymarketresearch.com/cardiovascular-drugs-market.html The World Health … development and growing number of medical trials are expected to have to … to retail Seloken along with related Logimax fixed-dose combination treatments all …
-
AstraZeneca lung cancer trial results impress but risks remain, analysts say
11 Sep 2017 16:51 GMT
… treatments Imfinzi and Tagrisso, sending its shares higher today.
The pharmaceutical … the European Society of Medical Oncology (ESMO) in … the company’s remaining trials, including Mystic’s … its heart failure drug Seloken to Italian drugmaker Recordati.
In …
-
RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE
22 May 2017 06:03 GMT
… of the rights to Seloken®/Seloken® ZOK (metoprolol succinate) … of cardiac rhythm, maintenance treatment after myocardial infarction, and … is a widely used drug in all European … of medical representatives promotes a wide range of innovative pharmaceuticals, …
-
AstraZeneca to rake in more than £450m on two drug sales
03 Jul 2017 12:08 GMT
… at least £450m on two drug sales, as the FTSE 100 … rights to migraine treatment Zomig and beta-blocker Seloken to two continental … phase three clinical trial for a combination immunotherapy treatment for lung cancer …
-
RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED
03 Jul 2017 08:02 GMT
… the rights to Seloken®/Seloken® ZOK (metoprolol succinate … succinate and felodipine) treatments in Europe. Metoprolol succinate … a widely used drug in all European countries … medical representatives promotes a wide range of innovative pharmaceuticals, …
-
ASTRAZENECA : COMPLETES AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
03 Jul 2017 06:14 GMT
… agreement-with-recordati-for-seloken-in-europe-22052017.html … the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate … of prescription medicines, primarily for the treatment of diseases … agreement-with-recordati-for-seloken-in-europe,c2301108
http …
-
Grünenthal to Buy Ex-Japan Global Rights to AstraZeneca's Migraine Drug for Up to $302M
07 Jun 2017 14:40 GMT
… acute treatment of cluster headaches. The U.K. drugmaker said … been licensed to Impax Pharmaceuticals, which will continue to … and response to pain medications.
Last month, AstraZeneca … metoprolol beta blocker brands Seloken®/Seloken® ZOK and metoprolol …
-
AstraZeneca sells its migraine drug for up to $302m
07 Jun 2017 09:34 GMT
… its migraine drug to Germany's Grunenthal.
The pharmaceuticals giant said … to focus instead on new medicines for cancer and other diseases … $300m European rights deal for Seloken with Recordati
Gabriel Baertschi, chief …
-
Recordati to buy AstraZeneca’s European beta-blocker treatments for $300m
23 May 2017 09:10 GMT
… pharmaceutical firm Recordati has agreed to acquire AstraZeneca’s metoprolol-based treatments … potential of the Seloken brands, which are mature medicines for the new … : “Metoprolol is a widely used drug in all European countries and …